 Outlook Therapeutics, Inc. OTLK the Company, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the successful closing of its previously announced private placement of 16.0 million of common stock at a price of 1.00 per share representing a 34 premium at signing to Syntone Ventures LLC, a U.S.-based affiliate of Syntone Technologies Group Co. Ltd. Outlook Therapeutics intends to use the net proceeds from the financing for working capital and general corporate purposes, including in support of its development program for ONS-5010 LYTENAVATM bevacizumab-vikg, an investigational ophthalmic formulation of bevacizumab to treat wet AMD, with approximately 0.9 million of the proceeds being used to fund its initial capital contribution to the planned PRC joint venture with Syntone. 